文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

瑞扎芬净对比卡泊芬净治疗念珠菌血症与侵袭性念珠菌病(ReSTORE):多中心、双盲、双模拟、随机3期试验

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
PubMed 文献 · Lancet · 2022-11-25
一句话结论ReSTORE 3期试验显示,瑞扎芬净治疗念珠菌血症/侵袭性念珠菌病在第14天整体治愈率(EMA)和30天全因死亡率(FDA)上非劣于卡泊芬净。

ReSTORE 是在15个国家66个三级中心开展的多中心、双盲、双模拟、随机3期试验,纳入199例有全身症状且真菌学确诊的念珠菌血症或侵袭性念珠菌病成人患者,1:1随机接受静脉瑞扎芬净(第1周400 mg,之后每周200 mg,共2–4剂)或静脉卡泊芬净(第1天70 mg负荷,之后50 mg每日一次),疗程不超过4周。第14天整体治愈率瑞扎芬净组59%(55/93)vs 卡泊芬净组61%(57/94),加权治疗差-1.1%(95%CI -14.9至12.7);30天死亡或生存状态未知瑞扎芬净组24%(22/93)vs 卡泊芬净组21%(20/94),治疗差2.4%(95%CI -9.7至14.4),均落在20%非劣效界值内。安全性方面两组治疗中出现的不良事件和严重不良事件无令人担忧的趋势。作者认为这些3期结果支持瑞扎芬净的持续研发。

要点

  • 瑞扎芬净组第14天整体治愈55/93(59%)vs 卡泊芬净组57/94(61%),加权治疗差-1.1%(95%CI -14.9至12.7),达到EMA主要终点非劣效。
  • 瑞扎芬净组30天死亡或生存状态未知22/93(24%)vs 卡泊芬净组20/94(21%),治疗差2.4%(95%CI -9.7至14.4),达到FDA主要终点非劣效。
  • 瑞扎芬净给药为静脉每周一次(第1周400 mg,之后每周200 mg,共2–4剂),卡泊芬净为第1天70 mg负荷后50 mg每日一次,疗程均不超过4周。
  • 安全性人群中瑞扎芬净组89/98(91%)vs 卡泊芬净组83/98(85%)发生至少1例治疗中出现的不良事件,严重不良事件分别为55/98(56%)vs 52/98(53%)。
  • 两组最常见(任一組≥5%)的治疗中出现不良事件为发热、低钾血症、肺炎、感染性休克和贫血。

适用人群与场景

  • 成人(≥18岁)有全身症状且真菌学确诊的念珠菌血症或侵袭性念珠菌病患者。
  • 改良意向治疗人群定义为接受至少1剂研究药物且随机前96小时内血培养或其他正常无菌部位培养记录念珠菌感染的患者。
  • 安全性人群定义为接受任意剂量研究药物的所有患者。

诊断标准与关键阈值

  • 整体治愈由临床治愈、影像学治愈和真菌学清除组成。
  • EMA主要终点为第14天整体治愈,非劣效界值20%。
  • FDA主要终点为30天全因死亡率(含生存状态未知),非劣效界值20%。

处置流程与药物剂量

  • 瑞扎芬净组:静脉瑞扎芬净每周一次,第1周400 mg,之后每周200 mg,共2–4剂,疗程不超过4周。
  • 卡泊芬净组:静脉卡泊芬净第1天70 mg负荷剂量,之后50 mg每日一次,疗程不超过4周。

研究设计与关键结果

  • 多中心、双盲、双模拟、随机3期试验,在15个国家66个三级中心开展,2018年10月12日至2021年8月29日筛查222例,随机199例(男118例[59%],女81例[41%],平均年龄61岁[SD 15.2]),瑞扎芬净组100例(50%)、卡泊芬净组99例(50%)。
  • 第14天整体治愈:瑞扎芬净组55/93(59%)vs 卡泊芬净组57/94(61%),加权治疗差-1.1%(95%CI -14.9至12.7)。
  • 30天死亡或生存状态未知:瑞扎芬净组22/93(24%)vs 卡泊芬净组20/94(21%),治疗差2.4%(95%CI -9.7至14.4)。
  • 安全性人群中至少1例治疗中出现的不良事件:瑞扎芬净组89/98(91%)vs 卡泊芬净组83/98(85%)。
  • 严重不良事件:瑞扎芬净组55/98(56%)vs 卡泊芬净组52/98(53%)。
  • 任一組发生率≥5%的治疗中出现不良事件包括发热、低钾血症、肺炎、感染性休克和贫血。

证据类型、等级与局限

  • 证据类型:多中心、双盲、双模拟、随机3期试验。
  • 作者结论:瑞扎芬净在第14天整体治愈(EMA)和30天全因死亡率(FDA)主要终点上非劣于卡泊芬净。
  • 作者指出:初始治疗数日的疗效值得评估;治疗中出现或严重不良事件无令人担忧的趋势。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于念珠菌血症或侵袭性念珠菌病成人患者,瑞扎芬净每周一次静脉给药方案在第14天整体治愈和30天全因死亡率上非劣于卡泊芬净每日给药方案。
  • 作者认为这些3期结果支持瑞扎芬净的持续研发。

指南或共识出处

  • ReSTORE试验,注册号ClinicalTrials.gov NCT03667690,由Cidara Therapeutics和Mundipharma资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis.

METHODS: ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries. Adults (≥18 years) with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were eligible for inclusion and randomly assigned (1:1) to receive intravenous rezafungin once a week (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses) or intravenous caspofungin (70 mg loading dose on day 1, followed by 50 mg daily) for no more than 4 weeks. The primary endpoints were global cure (consisting of clinical cure, radiological cure, and mycological eradication) at day 14 for the European Medical Agency (EMA) and 30-day all-cause mortality for the US Food and Drug Administration (FDA), both with a target non-inferiority margin of 20%, assessed in the modified intention-to-treat population (all patients who received one or more doses of study drug and had documented Candida infection based on a culture from blood or another normally sterile site obtained within 96 h before randomisation). Safety was evaluated by the incidence and type of adverse events and deaths in the safety population, defined as all patients who received any amount of study drug. The trial is registered with ClinicalTrials.gov, NCT03667690, and is complete.

FINDINGS: Between Oct 12, 2018, and Aug 29, 2021, 222 patients were screened for inclusion, and 199 patients (118 [59%] men; 81 [41%] women; mean age 61 years [SD 15·2]) were randomly assigned (100 [50%] patients to the rezafungin group and 99 [50%] patients to the caspofungin group). 55 (59%) of 93 patients in the rezafungin group and 57 (61%) of 94 patients in the caspofungin group had a global cure at day 14 (weighted treatment difference -1·1% [95% CI -14·9 to 12·7]; EMA primary endpoint). 22 (24%) of 93 patients in the rezafungin group and 20 (21%) of 94 patients in the caspofungin group died or had an unknown survival status at day 30 (treatment difference 2·4% [95% CI -9·7 to 14·4]; FDA primary endpoint). In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events that occurred in at least 5% of patients in either group were pyrexia, hypokalaemia, pneumonia, septic shock, and anaemia. 55 (56%) patients in the rezafungin group and 52 (53%) patients in the caspofungin group had serious adverse events.

INTERPRETATION: Our data show that rezafungin was non-inferior to caspofungin for the primary endpoints of day-14 global cure (EMA) and 30-day all-cause mortality (FDA). Efficacy in the initial days of treatment warrants evaluation. There were no concerning trends in treatment-emergent or serious adverse events. These phase 3 results show the efficacy and safety of rezafungin and support its ongoing development.

FUNDING: Cidara Therapeutics and Mundipharma.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Thompson GR, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2022. PMID: 36442484. doi:10.1016/S0140-6736(22)02324-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。